AYA.AX Artrya Limited ASX +9.39% to A$5.01 on 12 Jan 2026: AI stock outlook
AYA.AX stock led today’s AI health-tech moves after Artrya Limited (AYA.AX) closed at A$5.01, up 9.39% on 12 Jan 2026 as the ASX session ended. Trading volume reached 657,575.00 and the day range was A$4.78–A$5.24, showing renewed investor interest in Artrya’s Salix AI. The stock’s 50-day average is A$3.80 and the 200-day average is A$2.01, signalling a strong momentum shift for this Australian healthcare AI name. We examine valuation, technicals, Meyka AI grade and the forecast that underpins short and medium-term price targets.
AYA.AX stock: market move and quick facts
Artrya Limited (AYA.AX) closed the ASX session at A$5.01, a A$0.43 gain or 9.39% on 12 Jan 2026, with 657,575.00 shares traded. The company’s market capitalisation is A$515,606,000.00, EPS (TTM) is -0.18, and PE is -25.28, reflecting current losses while investors price future AI-driven revenue growth.
AYA.AX stock business model and AI product
Artrya develops Salix, a cloud-based AI that automates coronary CT angiography detection to flag coronary artery disease, positioning AYA.AX stock in the Medical – Healthcare Information Services subsector. Commercial adoption in clinics and imaging centres will drive recurring SaaS revenue if clinical validation and reimbursement milestones progress.
AYA.AX stock financials and valuation snapshot
Key metrics show operating stress but strong balance liquidity: current ratio 8.27, cash per share A$0.11, and book value per share A$0.21. Price-to-book is 22.02, price-to-sales is 18,414.50, and free cash flow per share is -0.14, underscoring growth-stage valuation and the need for revenue scale to justify multiples.
AYA.AX stock technicals and trading signals
Momentum indicators are bullish: RSI 70.89 (near overbought), ADX 40.86 (strong trend), and MACD histogram 0.09, while Bollinger upper band sits at A$5.17, matching today’s high A$5.24. Average volume is 919,618.00, so current volume shows moderate follow-through rather than peak conviction.
Meyka AI grade and AYA.AX stock forecast
Meyka AI rates AYA.AX with a score out of 100: 66.91 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects A$6.67 at one year and A$13.09 at three years; versus the current A$5.01, the one-year implied upside is 33.05%. Forecasts are model-based projections and not guarantees.
AYA.AX stock risks and sector context
Major risks include limited revenue history, negative margins, and high valuation metrics relative to healthcare peers where average PB is 5.93 in Australia’s Healthcare sector. Upside catalysts include regulatory approvals, hospital roll-outs, and reimbursement wins that convert clinical proof into steady revenue.
Final Thoughts
Artrya (AYA.AX) closed the ASX session at A$5.01 on 12 Jan 2026 after a 9.39% intraday rally, driven by AI sector interest and improving technicals. The company operates a high-potential clinical AI product, Salix, but financials show negative EPS -0.18, free cash flow per share -0.14, and a price-to-book of 22.02, so valuation assumes successful commercial scaling. Meyka AI’s forecast model projects A$6.67 in 12 months, implying 33.05% upside versus the current price; longer-term model targets A$13.09 at three years. Given the B (66.91) Meyka grade and the cash runway signals, we see AYA.AX stock as a watchlist candidate for investors seeking AI exposure in healthcare, with meaningful binary catalysts ahead. Remember, forecasts are projections and not guarantees, and investors should weigh execution risk and sector comparisons before deciding. For a company page and live data see the Meyka stock page for AYA.AX and recent market coverage on Markets Insider source and analysis on Markets Insider source.
FAQs
What drove AYA.AX stock higher on 12 Jan 2026?
AYA.AX stock rose after increased buying interest in AI healthcare names, a close at A$5.01 and technical strength near the 50-day average. Volume of 657,575.00 supported the move, though no single news release was cited.
What is Meyka AI’s view on AYA.AX stock?
Meyka AI rates AYA.AX with a score out of 100: 66.91 (Grade B, suggestion HOLD). The grade factors in benchmarks, sector performance, financial growth, key metrics and analyst consensus.
What price targets exist for AYA.AX stock?
Meyka AI’s forecast model projects A$6.67 at one year and A$13.09 at three years, implying a one-year upside of about 33.05% from A$5.01. Forecasts are model-based projections and not guarantees.
What are the main risks for AYA.AX stock?
Key risks include limited revenue scale, negative EPS (TTM -0.18), high valuation ratios such as PB 22.02, and execution risk for clinical roll-outs and reimbursement.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
